Mapi, a global health research and commercialization services company, has completed the acquisition of select Optum Life Sciences services, including North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes Research (HEOR) teams.

“Today’s therapeutics market is driven by patient outcomes and treatment value proven by real-world evidence. This acquisition enables Mapi to strengthen our industry-leading expertise and integrated solutions to help our clients accelerate market adoption of their novel therapeutics,” said James Karis, Mapi’s CEO. “With this acquisition, we also are the largest independent company exclusively dedicated to health research and commercialization services.”

With the addition of these new services and experts, Mapi has expanded its team across the Americas, Europe and Asia Pacific. Mapi has expanded its experience in strategic regulatory services, epidemiology, strategic market access, health economics outcomes research, patient centered outcomes, language services, patient insights, direct to patient support and real-world evidence.